Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07823270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma

Name: Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07823270)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorHebei Medical University Fourth Hospital

Started2026-10

View on ClinicalTrials.gov ↗

Hebei Medical University Fourth Hospital

53 trials monitored

See 1 trial at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

This study aims to evaluate the efficacy and safety of neoadjuvant sacituzumab tirumotecan (SKB264/MK-2870) combined with toripalimab in patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC). Eligible participants will receive 3 cycles of neoadjuvant treatment, followed by radical surgery. The primary endpoint is the pathologic complete response (pCR) rate.

Trial Details

NCT Number	NCT07823270
Lead Sponsor	Hebei Medical University Fourth Hospital
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	33 participants
Start Date	2026-10
Primary Completion	2028-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-16